Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > NASH partnership

<< Previous

Bullboard Posts

Next >>

Comment by ANALIAS00on Mar 09, 2021 11:20am

85 Views

Post# 32752488

RE:RE:NASH partnership

So Fred suddently you care about impact of a bad decision for shareholders ? You should not, SP may still double in the next two year an a half. So who cares ? :o))

FredTheVoice wrote: Jeffm34,

So Th bought back the rights for EGRIFTA,

And now, they will give some away again ?

Bad move in my opinion......

What if Oncology makes the stock rise so nicely in the next year, that the next financing, lets say, at 16$C, makes everyone very happy.....

FTV.